Dupilumab for treating severe asthma has now been rescheduled into the work programme. The second committee discussion of dupilumab for treating severe asthma will take place on committee on Thursday 12 November 2020. The topic webpage will be updated with the new timelines and expected publication date in due course.
The new timelines are subject to staff capacity and the ongoing management of the COVID-19 situation and we will continue to review our plans and update our stakeholders accordingly.